Prophylaxis with Isavuconazole or Posaconazole Protects Immunosuppressed Mice from Pulmonary Mucormycosis
Prophylaxis with Isavuconazole or Posaconazole Protects Immunosuppressed Mice from Pulmonary Mucormycosis
复制标题
DOI：
10.1128/aac.02589-16
复制
发表时间：
2017-05-01
影响因子：
4.9
通讯作者：
Ibrahim, Ashraf S.
中科院分区：
文献类型：
--
作者：
Gebremariam, Teclegiorgis;Alkhazraji, Sondus;Ibrahim, Ashraf S.
We assessed prophylactic or continuous therapy of isavuconazole, posaconazole, or voriconazole in treating pulmonary murine mucormycosis. In the prophylaxis studies, only isavuconazole treatment resulted in significantly improved survival and lowered tissue fungal burden of immunosuppressed mice infected with Rhizopus delemar. In the continuous treatment studies, isavuconazole and posaconazole, but not voriconazole, equally prolonged survival time and lowered tissue fungal burden compared to placebo-treated mice. These results support the use of isavuconazole and posaconazole in prophylaxis treatment.
